drugset
drugset / Trial / NCT03196765

Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy

NCT03196765 ↗

Phase 1/2 Withdrawn NeuroVia, Inc.
SequentialOpen-labelTreatment

Summary

This is a phase I/II, open label dose escalation study of multiple dose levels of NV1205 with a long-term treatment phase.

Timeline

Start
2018-08
Primary completion
2020-12-01
Completion
2020-12-01

Outcome

Outcome not reported

Stopped (Business): “No funding”

Drugs

EvaluationDrugModalityDoseRoute
Subject Sobetirome Small molecule — Oral

Indications

X-linked cerebral adrenoleukodystrophy